Type of information: Commercialisation agreement
Compound: next?generation sequencing (NGS)?based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti?TNF? therapy
Company: HTG Molecular Diagnostics (USA - AZ) Firalis (France)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Type agreement: licensing, commercialisation
Action mechanism: theranostic test
Disease: rheumatoid arthritis
- • On May 7, 2018, HTG Molecular Diagnostics, a provider of instruments, reagents and services for molecular profiling applications, and Firalis, a provider of bioanalytical services and biomarker-based products and services, announced a non?exclusive license and supply agreement that will enable Firalis to commercialize a next?generation sequencing (NGS)?based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti?TNF? therapy, and other research products and services for mRNA profiling of inflammatory?autoimmune disorders.
- The agreement is a next step in the parties’ relationship following the successful adaptation of Firalis’ BIOPRED* research?use assay to HTG EdgeSeq technology. Under the agreement, HTG will supply assay components to Firalis, who will manufacture, obtain applicable regulatory approvals for and sell the BIOPRED assay as kits and Firalis-based services in the applicable diagnostic and research fields worldwide. All such kits and services will be automated on HTG EdgeSeq systems purchased directly from HTG by end users.